Avanir migraine drug-device combo under FDA review
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review the new drug application (NDA) for Avanir Pharmaceuticals' AVP-825, an investigational drug-device combination, as an acute treatment for migraines.